We can't find the internet
Attempting to reconnect
Something went wrong
Hang in there while we get back on track
£495.00
It has never been this cheap. We have no record of a lower price.
£495 today · cheaper than every other day in the last 3 months
The 2023-2028 Outlook for Chlamydia Infection Diagnostics and Therapeutics in Japan
We'll watch every seller, every day. One email when your price arrives.
Price History & Forecast
Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.
Last 91 days · 91 data points
Historical
Generating forecast…
NEW HERE?
Amazon shows you one price. We show you all of them.
Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.
WHAT'S ON THIS PAGE
↑ Price chart
when this has been cheap or pricey
when this has been cheap or pricey
↑ Forecast
where the price is heading next
where the price is heading next
↓ Statistics
all-time high & low, recent range
all-time high & low, recent range
↑ Price alert
name your number, we'll email you
name your number, we'll email you
Price Distribution
Price distribution over 91 days • 1 price levels
Price Analysis
Most common price: £495 (91 days, 100.0%)
Price range: £495 - £495
Price levels: 1 different prices over 91 days
Description
This study covers the latent demand outlook for chlamydia infection diagnostics and therapeutics across the prefectures and cities of Japan. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 1,000 cities in Japan. For each city in question, the percent share the city is of its prefecture and of Japan as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each prefecture and city, latent demand estimates are created for chlamydia infection diagnostics and therapeutics. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of chlamydia infection diagnostics and therapeutics as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott Laboratories, Becton, Dickinson and Company, bioMerieux, Bio-Rad Laboratories, Danaher Corporation, DiaSorin, F. Hoffmann-La Roche, Novartis, Siemens AG, and Thermo Fisher Scientific. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).
Product Specifications
- Format
- paperback
- ASIN
- B0BP9YD12M
- Category
- Books > Subjects
- Domain
- Amazon UK
- Release Date
- 28 November 2022
- Listed Since
- 07 December 2022
Similar Products You Might Like
99% match
The 2023-2028 Outlook for Chlamydia Infection Diagnostics in Japan
£495.00
04 Sep 2026
99% match
The 2023-2028 Outlook for Chlamydia Infection Diagnostics and Therapeutics in China
£495.00
25 Aug 2026
99% match
The 2023-2028 Outlook for Chlamydia Infection Diagnostics in China
£495.00
21 Aug 2026
99% match
The 2023-2028 Outlook for Chlamydia Infection Diagnostics and Therapeutics for US Zip Codes
£490.00
11 Sep 2026
99% match
The 2023-2028 Outlook for Chlamydia Infection Diagnostics and Therapeutics in India
£515.00
08 Sep 2026
99% match
The 2023-2028 Outlook for Chlamydia Infection Diagnostics and Therapeutics in the United States
£520.00
04 Sep 2026
99% match
The 2023-2028 Outlook for Chlamydia Infection Diagnostics in India
£515.00
12 Aug 2026
99% match
The 2023-2028 Outlook for Chlamydia Infection Diagnostics in the United States
£520.00
05 Sep 2026
99% match
The 2023-2028 Outlook for Chlamydia Infection Diagnostics for US Zip Codes
£490.00
11 Sep 2026
96% match
Chlamydia: Prevalence, Pathogenesis & Prevention (Public Health in the 21st Century)
£51.23
22 Sep 2026
95% match
Chlamydia: Intracellular Biology, Pathogenesis, and Immunity
ASM Press
£36.20
24 Sep 2026
94% match
Chlamydia trachomatis: Methods and Protocols: 2042 (Methods in Molecular Biology, 2042)
Humana
£88.21
30 Sep 2026
94% match
The 2021-2026 World Outlook for Sexually Transmitted Diseases (STD) Treatments and Diagnoses
£795.00
12 Aug 2026
94% match
The 2023-2028 Outlook for Gonorrhea Therapeutics in Japan
£495.00
18 Sep 2026
94% match
The 2023-2028 Outlook for Gonorrhea Therapeutics in China
£495.00
20 Aug 2026
94% match
The 2021-2026 World Outlook for Sexually Transmitted Disease (STD) Diagnostic Testing
£795.00
10 Sep 2026
94% match
The 2023-2028 Outlook for Clinical Chemistry Analyzers in Japan
£495.00
20 Aug 2026
94% match
The 2023-2028 Outlook for Gonorrhea Therapeutics in the United States
£520.00
02 Sep 2026
94% match
Chlamydia pneumoniae: Infection and Disease (Infectious Agents and Pathogenesis)
Springer
£115.59
24 Sep 2026
94% match
Chlamydia pneumoniae: Infection and Disease (Infectious Agents and Pathogenesis)
Springer
£185.42
28 Oct 2026
94% match
The 2023-2028 Outlook for Gonorrhea Therapeutics for US Zip Codes
£490.00
08 Sep 2026
94% match
The 2023-2028 Outlook for HPV and CMV Therapeutics in China
£495.00
29 Oct 2026
94% match
The 2016-2021 Outlook for Systemic Broad- And Medium-Spectrum Antibiotic Tetracyclines, Chlortetracycline, and Congeners in the United States
£595.00
20 Aug 2026
94% match
The 2016-2021 Outlook for Systemic Broad- And Medium-Spectrum Antibiotic Tetracyclines, Chlortetracycline, and Congeners in Greater China
£595.00
23 Aug 2026